Company Description

In May 2023, the U.S. Court of Appeals for the Second Circuit ruled in favor of Purdue Pharma's Chapter 11 Plan of Reorganization (the 'Plan'), affirming the Bankruptcy Court's September 2021 confirmation order and holding that the Plan is appropriate under the law. The case was heard before the Supreme Court of the United States in December 2023. The Company's Plan will deliver billions of dollars of value for victim compensation, opioid crisis abatement, and overdose rescue medicines. The company continue to operate fully, honoring existing relationships and meeting obligations to partners, customers, and consumers.